DOI: 10.1055/s-00000007

Aktuelle Urologie

Referenz

Plimack ER, Motzer RJ, Escudier B. et al.
Two-Year Efficacy and Safety Update: Phase III CheckMate 025 Study of Nivolumab vs Everolimus in Patients With Advanced Renal Cell Carcinoma (aRCC).
Abstracts from the NCRI Cancer Conferences 2016

Bibliographische Angaben herunterladen

Suchen in: